Amylyx Pharmaceuticals
Update in progressAMLX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharma focused on neurodegenerative and endocrine diseases in the United States. It develops Avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 for post-bariatric hypoglycemia and congenital hyperinsulinism. It also advances AMX0035 for Wolfram syndrome and progressive supranuclear palsy, AMX0114 for ALS, and AMX0318 for post-bariatric hypoglycemia. Founded 2013, Cambridge, MA.
Company score
- Sentiment
- -0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.11
- Governance
- -0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Joshua B. Cohen
- Founded2013
- Employees136
- Websiteamylyx.com
Identifiers
- ISINUS0321085088
- FIGIBBG00DP10YT5
- LEI549300N7RNU56EKK7U80
- CUSIP032108508
- CIK0001658551